Beyondspring Pharmaceuticals Inc., of New York, said the FDA notified the company that the phase I/II study with Opdivo (nivolumab, Bristol-Myers Squibb Co.) in combination with plinabulin for patients with metastatic non-small-cell lung cancer may proceed with enrolling patients.